Department of Health and Human Services
200 Independence Avenue, S.W.
Washington
D.C.
20201
United States
Tel: 877-696-6775
Website: http://www.hhs.gov/
Email: hhsmail@os.dhhs.gov
244 articles about Department of Health and Human Services
-
BARDA Expands Partnership With Evidation to Validate and Improve Machine Learning Models for Early Detection of Influenza-like Illness Using Wearables
10/17/2023
Evidation announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to fund the 2023 Influenza-like Illness Detect & Protect Studies.
-
Codagenix Announces BARDA Contract for Project NextGen Supporting Development of CoviLiv™ as an Intranasal COVID-19 Vaccine
10/3/2023
Codagenix Inc. announced that the BARDA has entered into a contract with Codagenix to support the costs of a Phase 2b clinical study of CoviLiv™ for the prevention of symptomatic COVID-19 in people who have completed their primary approved/authorized COVID-19 vaccine series and their last COVID-19 vaccine was at least 3 months beforehand.
-
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
10/3/2023
Vir Biotechnology, Inc. announced that the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response, has awarded Vir approximately $50 million in new funding to advance the development of novel monoclonal antibody candidates and delivery solutions to widen the applicability of mAbs in COVID-19 and in pandemic preparedness and response.
-
Thymmune Therapeutics Receives $37M in Funding from the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H)
9/29/2023
Thymmune Therapeutics announced that the U.S. Department of Health and Human Services, through the Advanced Research Projects Agency for Health has awarded up to $37 million in funding to the Thymus Rejuvenation project.
-
ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats
9/28/2023
ModeX Therapeutics Inc., an OPKO Health, Inc. company, has been awarded a contract from the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, to advance a platform and specific candidates designed to address a range of public health threats in viral infectious diseases.
-
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
9/27/2023
MediciNova, Inc. announced the results of the nonclinical studies conducted under its contract with the BARDA, part of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services, to repurpose MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage such as acute respiratory distress syndrome and acute lung injury.
-
Delegation from U.S. Department of Health and Human Services, U.S. Food and Drug Administration, and Local Government Officials Visit Amneal Manufacturing Site in India
8/29/2023
Amneal Pharmaceuticals, Inc. announced that a delegation of senior members of the U.S. Department of Health and Human Services and U.S. Food and Drug Administration together with local government officials recently visited the Company’s manufacturing facility in Matoda, India.
-
ATCC Announces New Award from BARDA to Further Support its Medical Countermeasures Clinical Studies Network
6/27/2023
ATCC, the world’s premier biological materials management and standards organization, announced a Task Order award with the Biomedical Advanced Research and Development Authority, a component of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services.
-
National Association for Behavioral Healthcare Welcomes HHS Secretary Xavier Becerra to 2023 Annual Meeting!
6/12/2023
U.S. Health and Human Services Department Secretary Xavier Becerra will kick off the National Association for Behavioral Healthcare's 2023 Annual Meeting at the Salamander Washington, D.C.
-
MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
3/9/2023
MediciNova, Inc. announced a modification to its contract with the BARDA, a part of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services, to repurpose MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage such as acute respiratory distress syndrome and acute lung injury.
-
New Health+™ Long COVID Report Translates Lived Experiences into Evidence-Based Recommendations
11/30/2022
The US Department of Health and Human Services and its Office of the Assistant Secretary of Health recently released a Health+ Long COVID Human-Centered Design Report produced by Coforma's Health+™ program.
-
HDT Bio Selected to Join BLUE KNIGHT™
11/7/2022
HDT Bio Corp. announced it has been selected to join Blue Knight, a collaboration between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority within the Administration for Strategic Preparedness and Response, a part of the U.S. Department of Health and Human Services.
-
HHS and the Cohen Foundation Name T2 Biosystems a Phase 1 Winner in LymeX Diagnostics Prize
11/7/2022
T2 Biosystems, Inc. announced that the U.S. Department of Health and Human Services and the Steven & Alexandra Cohen Foundation have selected T2 Biosystems as a Phase 1 winner in the LymeX Diagnostics Prize, a LymeX Innovation Accelerator prize competition to accelerate the development of Lyme disease diagnostics.
-
ABL Awarded $Multimillion Contract to Provide Manufacturing and Nonclinical Services to Support Development of Promising Therapeutics for the NINDS
11/4/2022
Advanced BioScience Laboratories announced it is one of three contractors awarded an Indefinite Delivery, Indefinite Quantity contract for "Manufacturing and Nonclinical Studies support for Development of Therapeutic Biotechnology Products for Neurological-related Disorders" by the NINDS of the NIH of the HHS.
-
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
10/4/2022
Vir Biotechnology, Inc. announced that the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response, has awarded Vir a multi-year contract with the potential for up to $1 billion to advance the development of a full portfolio of innovative solutions to address influenza and potentially other infectious disease threats.
-
Centene Subsidiary Selected to Continue Serving Nebraska's Medicaid Managed Care Members
9/26/2022
Centene Corporation announced that its Nebraska subsidiary, Nebraska Total Care, has been awarded the Nebraska Department of Health and Human Services statewide Medicaid managed care contract.
-
Cases of monkeypox are growing at an alarming rate and Bavarian Nordic, the company that owns one of the two approved vaccines, may no longer be able to keep up.
-
American Nurses Association Calls for a Swift and Coordinated Response to Contain the Monkeypox Outbreak
8/5/2022
The US Department of Health and Human Services Secretary Xavier Becerra has declared the monkeypox outbreak to be a public health emergency.
-
The complaint alleges the agencies made an error under the Administrative Procedure Act, violating the Food Drug and Cosmetics Act by failing to approve Lumryz.
-
Sonic Healthcare USA authorized by HHS to perform testing for the Monkeypox Virus
7/5/2022
Sonic Healthcare USA was selected as one of five commercial laboratories authorized by the US Department of Health and Human Services through the Centers for Disease Control and Prevention to begin test validation using the CDC Non-variola Orthopoxvirus, high complexity NAAT molecular assay to identify Monkeypox.